70 174

Cited 0 times in

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

DC Field Value Language
dc.description.abstractBackground: Sasanlimab is an antibody to the programmed cell death protein 1 receptor. We report updated data of subcutaneous sasanlimab in non-small-cell lung cancer (NSCLC) and urothelial carcinoma dose expansion cohorts from a first-in-human phase Ib/II study. Patients and methods: Patients were ≥18 years of age with NSCLC or urothelial carcinoma, and no prior immunotherapies, who progressed on or were intolerant to systemic therapy, or for whom systemic therapy was refused or unavailable. Patients received subcutaneous sasanlimab at 300 mg every 4 weeks (q4w). Primary objectives were to evaluate safety, tolerability, and clinical efficacy by objective response rate (ORR). Results: Sixty-eight and 38 patients with NSCLC and urothelial carcinoma, respectively, received subcutaneous sasanlimab. Overall, sasanlimab was well tolerated; 13.2% of patients experienced grade ≥3 treatment-related adverse events. Confirmed ORR was 16.4% and 18.4% in the NSCLC and urothelial carcinoma cohorts, respectively. ORR was generally higher in patients with high programmed death-ligand 1 (PD-L1) expression (≥25%) and high tumor mutational burden (TMB; >75%). In the NSCLC and urothelial carcinoma cohorts, median progression-free survival (PFS) was 3.7 and 2.9 months, respectively; corresponding median overall survival (OS) was 14.7 and 10.9 months. Overall, longer median PFS and OS correlated with high PD-L1 expression and high TMB. Longer median PFS and OS were also associated with T-cell inflamed gene signature in the urothelial carcinoma cohort. Conclusions: Subcutaneous sasanlimab at 300 mg q4w was well tolerated with promising clinical efficacy observed. Phase II and III clinical trials of sasanlimab are ongoing to validate clinical benefit. Subcutaneous sasanlimab may be a potential treatment option for patients with NSCLC or urothelial carcinoma.-
dc.relation.isPartOfESMO OPEN-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorB C Cho-
dc.contributor.googleauthorK Penkov-
dc.contributor.googleauthorI Bondarenko-
dc.contributor.googleauthorA Kurochkin-
dc.contributor.googleauthorJ Pikiel-
dc.contributor.googleauthorH K Ahn-
dc.contributor.googleauthorM E Korożan-
dc.contributor.googleauthorM Osipov-
dc.contributor.googleauthorS Odintsova-
dc.contributor.googleauthorF Braiteh-
dc.contributor.googleauthorA Ribas-
dc.contributor.googleauthorJ E Grilley-Olson-
dc.contributor.googleauthorI Lugowska-
dc.contributor.googleauthorV Bonato-
dc.contributor.googleauthorM A Damore-
dc.contributor.googleauthorW Yang-
dc.contributor.googleauthorI A Jacobs-
dc.contributor.googleauthorM Bowers-
dc.contributor.googleauthorM Li-
dc.contributor.googleauthorM L Johnson-
dc.subject.keywordnon-small-cell lung cancer-
dc.subject.keywordphase I-
dc.subject.keywordurothelial carcinoma-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.identifier.bibliographicCitationESMO OPEN, Vol.8(4) : 101589, 2023-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.